Literature DB >> 8039107

Epidermal growth factor receptor overexpression in esophageal carcinoma. An immunohistochemical study correlated with clinicopathologic findings and DNA amplification.

Y Itakura1, H Sasano, C Shiga, Y Furukawa, K Shiga, S Mori, H Nagura.   

Abstract

BACKGROUND: Many studies have reported the increased expression of epidermal growth factor receptor (EGFR) in various human malignancies and its association with the biologic behavior of the tumors.
METHODS: We performed an immunohistochemical analysis of the EGFR in 217 cases of human esophageal squamous cell carcinoma, 161 lymph node metastases and 23 foci of squamous dysplasias. The findings were correlated with clinicopathologic features, including the clinical outcome. Southern blot analysis was performed in 42 cases for the detection of DNA amplification of the EGFR gene and subsequently was correlated with EGFR immunoreactivity.
RESULTS: Epidermal growth factor receptor overexpression was detected in 71% of primary tumors and 88% of lymph node metastases, as compared to nonpathologic adjacent esophageal epithelium. Statistically significant correlations were observed between EGFR overexpression and sex, age, histologic type, and the presence of invasion. Tumor staining was classified into two patterns, homogeneous and heterogeneous, based on the distribution of EGFR-positive cells. The immunostaining patterns of primary tumors had a statistically significant correlation with histologic type, the presence of adventitial invasion, histologic stage and lymph node metastasis. There was a tendency toward a worse prognosis for those patients with EGFR overexpression in the primary tumor. Greater than 90% of the foci of squamous dysplasia demonstrated homogeneous EGFR overexpression. DNA amplification of the EGFR was observed in 21% of primary tumors, and all demonstrated immunohistochemical overexpression.
CONCLUSIONS: Immunohistochemical overexpression of the EGFR, which was more frequent than EGFR DNA amplification, appears to play an important role in biologic behavior of human esophageal squamous cell carcinomas.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8039107     DOI: 10.1002/1097-0142(19940801)74:3<795::aid-cncr2820740303>3.0.co;2-i

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  69 in total

1.  Monoclonal antibody (MAB) in patients with advanced cancer.

Authors:  Hyung L Kim; Allan J Pantuck; Nazy Zomorodian; Arie S Belldegrun
Journal:  Curr Urol Rep       Date:  2003-02       Impact factor: 3.092

Review 2.  Neoadjuvant treatment of esophageal cancer.

Authors:  Nicholas P Campbell; Victoria M Villaflor
Journal:  World J Gastroenterol       Date:  2010-08-14       Impact factor: 5.742

3.  Epidermal growth factor receptor and mutant p53 expand an esophageal cellular subpopulation capable of epithelial-to-mesenchymal transition through ZEB transcription factors.

Authors:  Shinya Ohashi; Mitsuteru Natsuizaka; Gabrielle S Wong; Carmen Z Michaylira; Katharine D Grugan; Douglas B Stairs; Jiri Kalabis; Maria E Vega; Ross A Kalman; Momo Nakagawa; Andres J Klein-Szanto; Meenhard Herlyn; J Alan Diehl; Anil K Rustgi; Hiroshi Nakagawa
Journal:  Cancer Res       Date:  2010-04-27       Impact factor: 12.701

Review 4.  Multi-modality therapy for cancer of the esophagus and GE junction.

Authors:  Mohamedtaki A Tejani; Barbara A Burtness
Journal:  Curr Treat Options Oncol       Date:  2012-09

Review 5.  ERBBs in the gastrointestinal tract: recent progress and new perspectives.

Authors:  William H Fiske; David Threadgill; Robert J Coffey
Journal:  Exp Cell Res       Date:  2008-11-07       Impact factor: 3.905

6.  Association of PYGO2 and EGFR in esophageal squamous cell carcinoma.

Authors:  Meysam Moghbeli; Mohammad Reza Abbaszadegan; Moein Farshchian; Mehdi Montazer; Reza Raeisossadati; Abbas Abdollahi; Mohammad Mahdi Forghanifard
Journal:  Med Oncol       Date:  2013-03-03       Impact factor: 3.064

7.  Preoperative cetuximab, irinotecan, cisplatin, and radiation therapy for patients with locally advanced esophageal cancer.

Authors:  Michael S Lee; Harvey J Mamon; Theodore S Hong; Noah C Choi; Panagiotis M Fidias; Eunice L Kwak; Jeffrey A Meyerhardt; David P Ryan; Raphael Bueno; Dean M Donahue; Michael T Jaklitsch; Michael Lanuti; David W Rattner; Charles S Fuchs; Peter C Enzinger
Journal:  Oncologist       Date:  2013-02-21

8.  Interleukin-21 can efficiently restore impaired antibody-dependent cell-mediated cytotoxicity in patients with oesophageal squamous cell carcinoma.

Authors:  M Watanabe; K Kono; Y Kawaguchi; Y Mizukami; K Mimura; T Maruyama; H Fujii
Journal:  Br J Cancer       Date:  2009-12-22       Impact factor: 7.640

9.  The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors.

Authors:  Carol M Lee; Ian F Tannock
Journal:  BMC Cancer       Date:  2010-06-03       Impact factor: 4.430

10.  Significance of elevated ERK expression and its positive correlation with EGFR in Kazakh patients with esophageal squamous cell carcinoma.

Authors:  Xiaobin Cui; Su Li; Tingting Li; Xuelian Pang; Shumao Zhang; Jing Jin; Jianming Hu; Chunxia Liu; Lan Yang; Hao Peng; Jinfang Jiang; Weihua Liang; Jing Suo; Feng Li; Yunzhao Chen
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.